L-α-lysophosphatidylinositol sodium [796963-91-2]

L-α-lysophosphatidylinositol sodium is an endogenous ligand of GPR55 and an endogenous cannabinoid neurotransmitter that is involved in controlling cell survival and tumor progression.

murine iPSC cardiomyocytes:778 nM (EC50)

Concentration‐response studies in murine iPSC cardiomyocytes demonstrated that L-α-lysophosphatidylinositol sodium‐induced DMR activity in a concentration‐dependent manner (EC50 = 778 nM) and that the time course of the DMR response was rapid in onset, reached peak activity at 10 minutes post application and persisted for the duration of the period of measurement (90 minutes). [1]

Challenging WT hearts with L-α-lysophosphatidylinositol sodium prior to the onset of global ischemia significantly increased infarct size compared to vehicle controls, whereas this was not seen in seen GPR55−/− hearts, confirming an action of L-α-lysophosphatidylinositol sodium at GPR55. L-α-lysophosphatidylinositol sodium increases myocardial infarct size in hearts from wild type, but not GPR55−/−, mouse hearts. [1]

DMSO: 4 mg/mL (6.73 mM), Sonication is recommended.